A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects

被引:52
|
作者
Bisogno, Tiziana [1 ,8 ]
Mahadevan, Anu [2 ]
Coccurello, Roberto [3 ]
Chang, Jae Won [4 ,5 ]
Allara, Marco [1 ]
Chen, Yugang [2 ]
Giacovazzo, Giacomo [3 ]
Lichtman, Aron [6 ]
Cravatt, Benjamin [4 ,5 ]
Moles, Anna [3 ,7 ]
Di Marzo, Vincenzo [1 ]
机构
[1] CNR, Inst Biomol Chem, Endocannabinoid Res Grp, I-80078 Pozzuoli, NA, Italy
[2] Organix Inc, Woburn, MA USA
[3] IRCCS Fdn Santa Lucia, Cell Biol & Neurobiol Inst IBCN, Rome, Italy
[4] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
[5] Scripps Res Inst, Dept Chem Physiol, La Jolla, CA 92037 USA
[6] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA USA
[7] Genomnia Srl, Milan, Italy
[8] Univ TorVergat, Dept Expt Med & Biochem Sci, Rome, Italy
关键词
inhibitor; diacylglycerol; cannabinoid; 2-arachidonoylglycerol; serine lipase; anti-obesity effects; HIGH-FAT DIET; ANTAGONISTS; HYDROLYSIS; PREFERENCE; RECEPTORS; OBESITY; SYSTEM;
D O I
10.1111/bph.12013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Purpose The development of potent and selective inhibitors of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG) via DAG lipases (DAGL) and is just starting to be considered as a novel and promising source of pharmaceuticals for the treatment of disorders that might benefit from a reduction in endocannabinoid tone, such as hyperphagia in obese subjects. Experimental Approach Three new fluorophosphonate compounds O-7458, O-7459 and O-7460 were synthesized and characterized in various enzymatic assays. The effects of O-7460 on high-fat diet intake were tested in mice. Key Results Of the new compounds, O-7460 exhibited the highest potency (IC50 = 690nM) against the human recombinant DAGL, and selectivity (IC50 > 10M) towards COS-7 cell and human monoacylglycerol lipase (MAGL), and rat brain fatty acid amide hydrolase. Competitive activity-based protein profiling confirmed that O-7460 inhibits mouse brain MAGL only at concentrations 10M, and showed that this compound has only one major off-target', that is, the serine hydrolase KIAA1363. O-7460 did not exhibit measurable affinity for human recombinant CB1 or CB2 cannabinoid receptors (Ki > 10M). In mouse neuroblastoma N18TG2 cells stimulated with ionomycin, O-7460 (10M) reduced 2-AG levels. When administered to mice, O-7460 dose-dependently (012mg center dot kg1, i.p.) inhibited the intake of a high-fat diet over a 14h observation period, and, subsequently, slightly but significantly reduced body weight. Conclusions and Implications O-7460 might be considered a useful pharmacological tool to investigate further the role played by 2-AG both in vitro and in vivo under physiological as well as pathological conditions. Linked Articles This article is part of a themed section on Cannabinoids. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.169.issue-4 & http://dx.doi.org/10.1111/bph.2012.167.issue-8
引用
收藏
页码:784 / 793
页数:10
相关论文
共 50 条
  • [31] Anti-obesity activity of hen egg anti-lipase immunoglobulin yolk, a novel pancreatic lipase inhibitor
    Hirose, Mai
    Ando, Taishi
    Shofiqur, Rahman
    Umeda, Kouji
    Kodama, Yoshikatsu
    Sa Van Nguyen
    Goto, Tsuyoshi
    Shimada, Masaya
    Nagaoka, Satoshi
    NUTRITION & METABOLISM, 2013, 10
  • [32] Anti-obesity activity of hen egg anti-lipase immunoglobulin yolk, a novel pancreatic lipase inhibitor
    Mai Hirose
    Taishi Ando
    Rahman Shofiqur
    Kouji Umeda
    Yoshikatsu Kodama
    Sa Van Nguyen
    Tsuyoshi Goto
    Masaya Shimada
    Satoshi Nagaoka
    Nutrition & Metabolism, 10
  • [33] Novel insights on anti-obesity potential of the miracle tree, Moringa oleifera: A systematic review
    Redha, Ali Ali
    Perna, Simone
    Riva, Antonella
    Petrangolini, Giovanna
    Peroni, Gabriella
    Nichetti, Mara
    Iannello, Giancarlo
    Naso, Maurizio
    Faliva, Milena Anna
    Rondanelli, Mariangela
    JOURNAL OF FUNCTIONAL FOODS, 2021, 84
  • [34] Physiological genomic approach to assess the anti-obesity potential of a novel weight loss supplement
    Bagchi, Debasis
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 239
  • [35] Anti-obesity potential of SGLT2 inhibitors in development for treatment of diabetes
    Washburn, William N.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [36] Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: Dopamine transporter occupancy as measured by PET
    Appel, Lieuwe
    Bergstrom, Mats
    Lassen, Jorgen Buus
    Langstrom, Bengt
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 (02) : 251 - 261
  • [37] Anti-obesity effects of angiotensin converting enzyme inhibitor are mediated by brown adipose tissue activation
    Zhai, Baiqiang
    Zhou, Huiqiao
    Chen, Li
    Qiu, Wanru
    Yang, Mingsheng
    Luo, Yunbo
    Liu, Xiaomeng
    SCIENCE BULLETIN, 2018, 63 (05) : 275 - 277
  • [38] ASP1941, a Novel SGLT2-Selective Inhibitor, Exerts Anti-Obesity Effects by Increasing Fatty Acid Oxidation in Diet-Induced Obesity Rats
    Takasu, Toshiyuki
    Hayashizaki, Yuka
    Mitsuoka, Keisuke
    Yokono, Masanori
    Kihara, Rumi
    Miyoshi, Sousuke
    Yoshida, Shigeru
    Kurosaki, Eiji
    DIABETES, 2011, 60 : A490 - A491
  • [39] Anti-obesity effects of galangin, a pancreatic lipase inhibitor in cafeteria diet fed female rats
    Kumar, Shiv
    Alagawadi, K. R.
    PHARMACEUTICAL BIOLOGY, 2013, 51 (05) : 607 - 613
  • [40] Surface display of pancreatic lipase inhibitor peptides by engineered Saccharomyces boulardii: Potential as an anti-obesity probiotic
    Nayebhashemi, Mahsa
    Enayati, Somayeh
    Zahmatkesh, Mozhgan
    Madanchi, Hamid
    Saberi, Samaneh
    Mostafavi, Ehsan
    Ardakani, Esmat Mirbzadeh
    Azizi, Mohammad
    Khalaj, Vahid
    JOURNAL OF FUNCTIONAL FOODS, 2023, 102